PrIMAVeRa

In-silico tools to evaluate the effect of vaccines on reduction of AMR

‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.

It is a European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.

A project sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including the models, once the project has finished.

PRIMAVERA is part of the AMR Accelerator Programme.

IMI AMR Accelerator_Slogan_square_RGB.png

At a glance

Innovations to accelerate vaccine development and manufacture

TIMELINE

01.11.2021-30.11.2026
(5 Years)

COORDINATOR

European Vaccine Initiative (EVI)

FUNDER

Innovative Medicines Initiative 2 (IMI2) and European Federation of Pharmaceutical Industries and Associations (EFPIA)

FUNDING

€9.25 Mio
(€6.5 Mio from IMI2 and €2.75 Mio from EFPIA)

Scientist on Computer_edited_edited
Conference
Add a Title
icon_PrIMAVeRA_crop
Laboratory
Drug and Syringe
Girl at the Pediatrician
Pipetting Samples
hand shake_Inno4Vac KoM_Source Wix
Add a Title
Preventive services
Add a Title